PSA Advisories

Medication Errors in Outpatient Hematology and Oncology Clinics

Oncology care is increasingly provided in outpatient settings because of its increased patient convenience and decreased cost. Reported medication errors in this setting have not been fully explored and give cause for examination. A query of the Pennsylvania Patient Safety Reporting System (PA-PSRS) database for reports from July 2015 through June 2017 in outpatient hematology and oncology clinics affiliated with hospitals or health systems revealed 1,015 reported medication errors. More than half (53.7%, n = 545) reached the patient. The most commonly reported event types included dose omissions (15.3%, n = 155) and wrong dose/over dosage (13.1%, n = 133). High-alert medications were reported in 55.5% (n = 563) of the events. Antineoplastic agents made up 94.3% (n = 531) of medication errors reported with high-alert medications. Due to the potential hazards associated with antineoplastic agents, special care is warranted to reduce the risk of errors associated with this class of medications. Error reduction strategies in outpatient hematology and oncology clinics begin with a risk assessment of medication use processes and focus on patient information, order communication, quality processes, and risk management. (Pa Patient Saf Advis 2017 Dec;14[4].)

Please click here for the complete article on the Pennsylvania Patient Safety Authority’s website.


More Alerts

Since the 2021-22 influenza (flu) vaccine became available last month, the Institute for Safe Medication Practices (ISMP) has received 16 cases of accidental influenza and coronavirus disease 2019 (COVID-19) vaccine mix-ups. All reports were sent by consumers or healthcare practitioners via one of
ISMP has received reports from two different hospitals about McKesson packaged levetiracetam 250 unit dose blister packages that have a barcode that scans as naproxen 500 mg. Apparently one side of the unit dose blister of 10 levetiracetam tablets scans properly, but the barcode on other side
URGENT – HAZARDOUS SITUATION – PLEASE REACT IMMEDIATELY ISMP is aware of an extremely hazardous packaging error involving certain cisatracurium products from Meitheal Pharmaceuticals. While the outer carton identifies the vials inside as cisatracurium, the vials contained in the carton are labeled